New perspectives for synergy research with the "omic"-technologies.
Synergistic effects, understood as true overadditive effects, are often observed in experimental and clinical studies using phytopharmaceuticals. The introduction of the "omic"-technologies is now opening new perspectives in rationalizing these effects and making use of them in the development of a new generation of phytopharmaceuticals. This review describes possible mechanism of synergistic actions of herbal drugs by mono- and multitargeting and by the activation of signal cascades. It examines the possibilities of the standardization of single and multi component plant extracts and the prediction and assessment of the toxicity and safety of plant extracts with the support of the "omic"-technologies. It further discusses the use of phytopharmaceuticals in the context of an "individualized medicine". It makes proposals how to use the "omic"-technologies to rationalize and develop combination therapies of phytopharmaceuticals and synthetic drugs to minimize adverse reactions (ARs) or improve the therapeutic efficacy. Examples of clinical studies are given which explore already the potential of such co-medications. Modern medical therapy has acknowledged for quite some time the usefulness of combination therapies in the treatment of multifactorial diseases like cancer, cardiovascular or rheumatic diseases. The term "synergy" is rarely used in this context, the combinatory mechanisms of actions seldom completely understood and the potentially occurring adverse reactions feared. A systematic exploitation of synergy effects of phytomedical interventions alone or in combination with synthetic drugs should lead in a long term perspective to the discovery and development of more rational evidence-based interventions in the prevention and therapy of multifactorial diseases and should thereby enrich modern pharmacotherapy.
Medical Policlinic of the Rheinische Friedrich-Wilhelms-University of Bonn, Wilhelmstr. 35-37, D-53111 Bonn, Germany. gudrun.ulrich-merzenich@ukb.uni-bonn.de
G
G
Ulrich-Merzenich
D
D
Panek
H
H
Zeitler
H
H
Wagner
H
H
Vetter
D004358:Drug Therapy; D023281:Genomics; D010936:Plant Extracts / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D040901:Proteomics
D010936:Plant Extracts